<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>Isfahan University of Medical Sciences</PublisherName>
				<JournalTitle>Journal of Isfahan Medical School</JournalTitle>
				<Issn>1027-7595</Issn>
				<Volume>26</Volume>
				<Issue>90</Issue>
				<PubDate PubStatus="epublish">
					<Year>2008</Year>
					<Month>09</Month>
					<Day>22</Day>
				</PubDate>
			</Journal>
<ArticleTitle>The evaluation of ARG expression in DLBCL staging</ArticleTitle>
<VernacularTitle>The evaluation of ARG expression in DLBCL staging</VernacularTitle>
			<FirstPage></FirstPage>
			<LastPage></LastPage>
			<ELocationID EIdType="pii">12997</ELocationID>
			
			
			<Language>FA</Language>
<AuthorList>
<Author>
					<FirstName>Faribourz</FirstName>
					<LastName>Mokarian</LastName>
<Affiliation>Assistant Professor, Department of Hematology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran</Affiliation>
<Identifier Source="ORCID">0000-0002-9874-298X</Identifier>

</Author>
<Author>
					<FirstName>Shahnaz</FirstName>
					<LastName>Amani</LastName>
<Affiliation>Nutritionist, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Zahra</FirstName>
					<LastName>Kabiri</LastName>
<Affiliation>General Practitioner, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran</Affiliation>

</Author>
<Author>
					<FirstName>Mansoor</FirstName>
					<LastName>Salehi</LastName>
<Affiliation>Associate Professor, Department of Genetics and Molecular Biology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran</Affiliation>

</Author>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>2010</Year>
					<Month>11</Month>
					<Day>07</Day>
				</PubDate>
			</History>
		    <Abstract>Background:            ARG is a   proto-oncogene and a member of a tyrosine kinase proteins family. It has   great importance in many cancers, but there is no conclusive evidence on its   role in DLBCL staging. The aim of this study was to evaluate importance of   ARG, in this cancer&#039;s staging.             Methods:         Sixteen DLBCL and   4 reactive lymph node (as control group) samples, after staging using Ann Arbor staging   system, were used in this study. Formaldehyde fixed paraffin embedded blocks   were prepared from the samples. After the sectioning, all samples were   hybridized with primary antibodies against ARG and GAPDH (as control house   keep keeping gene). The slides were then washed and hybridized with   fluorescently labeled secondary antibodies (ARG, green labeled and GAPDH,   red). After capturing the pictures using CCD camera, the intensity of green   and red colures was measured and the ratio between green/red, that   demonstrate changes in ARG expression, were calculated.             Findings:         The mean ratio of   green/red (ARG expression) was significantly different between reactive lymph   node, stage I, II and III of DLBCL. ARG expression was different between all   groups except for between stage III and VI of DLBCL.             Conclusion:         The observed   changes in ARG expression is a potential biomarker for DLBCL staging. In   addition specific inhibitors of ARG can be considered as new chemotherapy   agents in the DLBCL treatment.             Key words:         Lymphoma, ARG, DLBCL           </Abstract>
			<OtherAbstract Language="FA">Background:            ARG is a   proto-oncogene and a member of a tyrosine kinase proteins family. It has   great importance in many cancers, but there is no conclusive evidence on its   role in DLBCL staging. The aim of this study was to evaluate importance of   ARG, in this cancer&#039;s staging.             Methods:         Sixteen DLBCL and   4 reactive lymph node (as control group) samples, after staging using Ann Arbor staging   system, were used in this study. Formaldehyde fixed paraffin embedded blocks   were prepared from the samples. After the sectioning, all samples were   hybridized with primary antibodies against ARG and GAPDH (as control house   keep keeping gene). The slides were then washed and hybridized with   fluorescently labeled secondary antibodies (ARG, green labeled and GAPDH,   red). After capturing the pictures using CCD camera, the intensity of green   and red colures was measured and the ratio between green/red, that   demonstrate changes in ARG expression, were calculated.             Findings:         The mean ratio of   green/red (ARG expression) was significantly different between reactive lymph   node, stage I, II and III of DLBCL. ARG expression was different between all   groups except for between stage III and VI of DLBCL.             Conclusion:         The observed   changes in ARG expression is a potential biomarker for DLBCL staging. In   addition specific inhibitors of ARG can be considered as new chemotherapy   agents in the DLBCL treatment.             Key words:         Lymphoma, ARG, DLBCL           </OtherAbstract>
<ArchiveCopySource DocType="pdf">https://jims.mui.ac.ir/article_12997_ac5145d76cd82e2fb875e94ba0c5b4b4.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
